NEW YORK (TheStreet) -- VIVUS(VVUS) - Get Report surged Tuesday after the pharmaceutical company crushed analysts' estimates with its first-quarter report despite a sequential dip in prescriptions of Qsymia, its obesity treatment drug.

The company reported a loss of 13 cents a share, excluding items, compared to the loss of 53 cents a share in the same period one year earlier. This was far narrower than the estimate of a loss of 37 cents a share from analysts polled by Thomson Reuters.

First-quarter revenue totaled $36.7 million, up year over year from $4.1 million. This smashed the Zacks Consensus Estimate of $12 million. Revenue included $19.4 million in license and milestone revenue, $7.4 million in supply revenue and $0.8 million in royalty revenue tied to the erectile dysfunction drug Stendra.

Must Read:Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Vivus also reported approximately 121,000 Qsymia prescriptions dispensed in the first quarter, down from 124,000 in the fourth quarter 2013.

The stock was up 11.75% to $5.80 at 10:43 a.m.

Image placeholder title

VVUS data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.